Vanda - Wutah dodolan YoY sajrone rolas wulan kepungkur VNDA

Vanda Pharmaceuticals develops therapies for severe psychiatric disorders, leveraging patent protection for dosing regimens. The company occupies a protected niche in the treatment of rare sleep pathologies and schizophrenia. Comparable year-over-year sales growth over 12 months reflects revenue dynamics, where the value is recorded at 8.30. This confirms the issuer's strong pricing power within the orphan drug segment.
vandapharma.com (VNDA) - rincian metrik lan laporan keuangan

To objectively assess the operational efficiency of Vanda Pharmaceuticals (VNDA), investors must separate market noise from the actual dynamics of business expansion. Analyzing the TTM annual sales growth rate via a rolling annual interval allows for an assessment of demand stability for exclusive CNS drugs, determining whether Vanda Pharmaceuticals (VNDA) maintains its competitive advantages in niche markets or is facing a fundamental decline in revenue.